Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.An investigational drug being developed by AstraZeneca for the treatment of acute ischemic stroke has been shown to be as safe and as well tolerated as placebo when administered to intracerebral hemorrhage patients.
Subscribe to our email newsletter
The company wanted to access the safety and tolerability of the drug, NXY-059, in intracerebral hemorrhage (ICH) as treatment may be initiated before a scan has confirmed diagnosis of acute ischemic stroke (AIS).
The data showed that the safety and tolerability of NXY-059 in ICH patients was similar to placebo, with comparable mortality rates of 20% in each group.
“Our evolving understanding of the safety and tolerability profile of NXY-059 in acute stroke conditions is enhanced greatly by the CHANT trial results,” commented Dr Tomas Odergren, global product director for NXY-059 at AstraZeneca.
NXY-059 is currently being studied as a neuroprotectant in phase III clinical trials for the treatment of acute ischemic stroke by AstraZeneca. The compound was licensed from US biopharmaceutical company, Renovis, Inc.